0001140361-23-007486.txt : 20230216 0001140361-23-007486.hdr.sgml : 20230216 20230216164543 ACCESSION NUMBER: 0001140361-23-007486 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230214 FILED AS OF DATE: 20230216 DATE AS OF CHANGE: 20230216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wilson Martin CENTRAL INDEX KEY: 0001704342 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36829 FILM NUMBER: 23639087 MAIL ADDRESS: STREET 1: C/O TELIGENT, INC. STREET 2: 105 LINCOLN AVENUE CITY: BUENA STATE: NJ ZIP: 08310 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ROCKET PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001281895 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 350 FIFTH AVENUE STREET 2: SUITE 7530 CITY: NEW YORK STATE: NY ZIP: 10118 BUSINESS PHONE: 646-440-9100 MAIL ADDRESS: STREET 1: 350 FIFTH AVENUE STREET 2: SUITE 7530 CITY: NEW YORK STATE: NY ZIP: 10118 FORMER COMPANY: FORMER CONFORMED NAME: INOTEK PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20040226 4 1 form4.xml X0306 4 2023-02-14 0001281895 ROCKET PHARMACEUTICALS, INC. RCKT 0001704342 Wilson Martin C/O ROCKET PHARMACEUTICALS, INC. 9 CEDARBROOK DRIVE CRANBURY NJ 08512 true General Counsel Stock Option (Right to Buy) 20.04 2023-02-14 4 A 0 87147 0 A 2033-02-13 Common Stock 87147 87147 D Restricted Stock Units 2023-02-14 4 A 0 29079 0 A Common Stock 29079 29079 D This option represents a right to purchase a total of 87,147 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years. /s/ Martin Louis Wilson 2023-02-16